Bluebird Bio Raises $30 Million Series C To Accelerate Pipeline Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Gene therapy biotech hopes to move lead program for childhood cerebral adrenoleukodystrophy into a registrational trial later this year.